SOURCE: Market Pulse

April 27, 2010 08:30 ET

Market Pulse Breaking News Alert for Tuesday, April 27, 2010: MZEI -- Implications of Test Results Are Enormous to Medizone as the Potential Market for AsepticSure™ Has at Least Quadrupled in Size!

NOTE TO EDITORS: The Following Is an Investment Opinion Being Issued by Market Pulse.

ATLANTA, GA--(Marketwire - April 27, 2010) -  Market Pulse News Alert for this AM, Stocks to Watch are: Medizone International, Inc. (OTCBB: MZEI), NexMed Inc. (NASDAQ: NEXM), Ford Motor Co. (NYSE: F) and Hana Biosciences Inc. (OTCBB: HNAB).

Investors need to be watching Medizone International, Inc. (OTCBB: MZEI) this AM! Medizone International is a research and development company engaged in developing AsepticSure™ System, a novel ozone-based technology. AsepticSure™ is a portable decontamination and sterilization system for hospitals, government buildings, sports training facilities, schools and other critical infrastructure that might currently require, or need to be prepared for countermeasures capability from contamination by infectious biological agents. A government variant is being developed for bio-terrorism counter measures. Medizone began mockup trials in January 2010 for both public (hospital) and government (bio-terrorism countermeasures) applications. In March 2010, Medizone successful completed the first full round of room scale testing with its AsepticSure™ sterilization system. Successful decontamination by AsepticSure™ to the 6 log standard or greater has been demonstrated with C.difficile, E coli, Pseudomonas aeruginous, MRSA, VRE and Bacillius subtilis. The AsepticSure™ system is capable of decontamination to the previously unobtainable 6 log standard (99.9999% bactericidal kill) on all hospital surfaces, hard or soft. Medizone is now able to greatly reduce the time required to achieve 6 log kills on hard surfaces to 30 minutes of exposure. From a commercial viewpoint, the higher the "kill rate" in the shortest turnaround time, the more favorably physicians and hospital administrators will view the system. Given the outstanding range of bactericidal kill rates Medizone has achieved to date with the pathogens most often associated with hospital derived infections, it has become clear there are opportunities abounding to expand scientific horizons through collaborative arrangements in many diverse and exciting new applications. Biological contamination of medical treatment areas such as hospitals and chronic care facilities has recently been identified by several world renowned public health institutions, including the Centers for Disease Control, as one of the greatest threats to public health and safety in the industrial world. Hospital Acquired Infections (HAIs) are one of the most common complications of hospital care. Nearly 2 million patients develop HAIs, which contribute to 99,000 deaths each year and $28 billion to $33 billion in health care costs. Demand for an effective product is huge. Once the trial program for the AsepticSure™ hospital sterilization system is concluded, MZEI expects to out-source the manufacturing of the product and partner with large, well established companies that are already fully embedded in their sector of business as suppliers, such as medical device manufacturers or service companies. Medizone believes that a field hardened variant of the AsepticSure™ hospital unit currently being readied for scale up testing will have wide bio defense applications internationally as it will be easily deployable in response to virtually any terrorist assault, extremely effective against a broad range of lethal pathogens, easy to manage and maintain and most importantly, it has the potential to save lives. Medizone now believes that the performance profile of its AsepticSure™ Sterilization System will exceed all the prerequisite requirements of affordability, practicability and unmatched efficacy, which will catapult it into the world market. Medizone International, Inc. is poised to become a significant player in the healthcare industry! Medizone International, Inc. just had excellent news out in a press release before today's opening bell announcing that it has successfully sterilized both naturally and artificially contaminated sports equipment using its highly versatile AsepticSure™ sterilization system! The company also said the implications of these results are enormous to them as the potential market for AsepticSure™ has at least quadrupled in size! This could be great news for investors!

In response to the growing need for the decontamination of sports training facilities and locker rooms from the Super Bug Methicillin-Resistant Staphylococcus Aureus, also known as MRSA, Medizone International, Inc. (OTCBB: MZEI) is pleased to announce that it has successfully sterilized both naturally and artificially contaminated sports equipment using its highly versatile AsepticSure™ sterilization system. "The implications of these results are enormous to Medizone as the potential market for AsepticSure™ has at least quadrupled in size," stated Mr. Marshall, Medizone's CEO. As reported in a recent article entitled "Assessment of Athletic Facility Surfaces for MRSA in the Secondary School Setting" (Journal of Environmental Health, Feb., 2010) the authors stated that, "Methicillin-Resistant Staphylococcus Aureus (MRSA) was once largely a hospital-acquired infection, but increasingly, community-associated MRSA (CA-MRSA) is causing outbreaks among otherwise healthy people in athletic settings. Secondary school athletic trainers, student athletes, and the general student population may be at elevated risk of MRSA infection."

Part of the test program just completed by Medizone involved the evaluation of a hockey goalie's glove used for three years by a 12-year-old Canadian boy. The inside surface of the glove was found to be heavily contaminated with MRSA along with a number of other less deadly pathogens. Medizone's Director of Medical Affairs, Dr Michael Shannon stated, "Pads and team sweaters were also tested and very effectively sterilized without damaging the textiles or leather. It is noteworthy that the protocol used in gloves heavily contaminated with numerous real world pathogens needed to be adjusted significantly from the hospital protocol in order to obtain full sterilization, which demonstrates the ability of the AsepticSure™ system to meet the many varied demands in the real world through protocol changes without the need to alter the technology. This new work has lead to the development of a decontamination protocol specifically for this application which yields results consistent with those expected in hospital setting of 6 logs (99.9999%, sterilization standard) of bacterial kill. Thus, we have now demonstrated that the AsepticSure™ system is capable of cost effective hospital sterilization, locker room and sports equipment sterilization and in due course, we expect to assume a meaningful role in the bio-terrorism counter measures arena as well."

Medizone International, Inc. is a research and development company engaged in developing its AsepticSure™ System to decontaminate and sterilize hospital surgical suites, emergency rooms, intensive care units, schools and other critical infrastructure. A government variant is being developed for bio-terrorism counter measures.

Stocks in the news and acting well as of late include: NexMed Inc. (NASDAQ: NEXM), Ford Motor Co. (NYSE: F) and Hana Biosciences Inc. (OTCBB: HNAB).

Information contained herein is the opinion of ("MP") and is intended to be used strictly for informational purposes. You should be aware that MP attempts to assure itself of the accuracy of the information contained in the analyses it publishes. In this regard, MP does, at times, rely on the accuracy of information supplied to it by the companies which are the subject of MP's analyses and/or parties related to those companies. MP also relies on the accuracy and integrity of information that is contained in company press releases and reports filed with the SEC. The companies mentioned in this publication have not approved the content or timing of the information being published unless otherwise noted.

MP, because it relies on information supplied by various third parties disclaims any responsibility for the accuracy of such information. Any investor considering making an investment in any security which has been the subject of a MP analysis or opinion should, before making any such investment, consult with his/her market professional and/or do his/her own independent research regarding the company which is the subject of an MP opinion, recommendation or analysis. Information regarding companies which MP has opined upon is normally available from many sources including the subject company's filings with the SEC and various press releases issued by the company.

You should be aware that MP is often compensated for issuing analyses, recommendations or opinions concerning particular companies. Its opinion is therefore not unbiased and you should consider this factor when evaluating MP's statements regarding a company. MP has been compensated five thousand dollars from Medizone International, Inc. In addition, MP was also compensated two hundred fifty thousand restricted shares of Medizone International, Inc. by the company. MP's officers and directors reserve the right to buy additional shares of the companies discussed in this opinion and may profit in the event those shares rise in value. When MP receives shares as compensation for a profiled company, MP may sell part or all of any such shares during the period in which MP is performing such services. and Market Pulse Breaking News Alert are owned by Market Pulse LLC.

Contact Information